FI3529251T3 - Naftyridinonijohdannaisia ja niiden käyttö rytmihäiriön hoidossa - Google Patents
Naftyridinonijohdannaisia ja niiden käyttö rytmihäiriön hoidossa Download PDFInfo
- Publication number
- FI3529251T3 FI3529251T3 FIEP17801105.2T FI17801105T FI3529251T3 FI 3529251 T3 FI3529251 T3 FI 3529251T3 FI 17801105 T FI17801105 T FI 17801105T FI 3529251 T3 FI3529251 T3 FI 3529251T3
- Authority
- FI
- Finland
- Prior art keywords
- chloro
- dichlorophenyl
- naphthyridin
- aineet
- hydroxymethyl
- Prior art date
Links
- 206010003119 arrhythmia Diseases 0.000 title 1
- 230000006793 arrhythmia Effects 0.000 title 1
- VHSIAYLBCLUAFT-UHFFFAOYSA-N n-[3-acetyl-6-(4-chlorophenyl)-7-(2,4-dichlorophenyl)-1-methyl-2-oxo-1,8-naphthyridin-4-yl]acetamide Chemical class C=1C=C(Cl)C=CC=1C=1C=C2C(NC(=O)C)=C(C(C)=O)C(=O)N(C)C2=NC=1C1=CC=C(Cl)C=C1Cl VHSIAYLBCLUAFT-UHFFFAOYSA-N 0.000 title 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 5
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 4
- HVYWMOMLDIMFJA-UHFFFAOYSA-N 3-cholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 HVYWMOMLDIMFJA-UHFFFAOYSA-N 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 239000003146 anticoagulant agent Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- -1 (S)-8-chloro-1-(2,6- — dichlorophenyl)-5-(2,3-dihydroxypropoxy)-2-(hydroxymethyl)-1 ,6-naphthyridine Chemical compound 0.000 claims 1
- FWXGVUPQGGYNPO-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-2-(hydroxymethyl)-5-(3-hydroxypropyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CCCO FWXGVUPQGGYNPO-UHFFFAOYSA-N 0.000 claims 1
- XDAYAPJRCGNDON-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(1,2-dihydroxyethyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C(CO)O XDAYAPJRCGNDON-UHFFFAOYSA-N 0.000 claims 1
- LHOYPFIGBFSNOS-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(1,2-dihydroxyethyl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)C(CO)O LHOYPFIGBFSNOS-UHFFFAOYSA-N 0.000 claims 1
- VCMAAYDSJJLABR-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropoxymethyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)COCC(CO)O VCMAAYDSJJLABR-UHFFFAOYSA-N 0.000 claims 1
- HCTCNUKJFUGPRV-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,3-dihydroxypropyl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)CC(CO)O HCTCNUKJFUGPRV-UHFFFAOYSA-N 0.000 claims 1
- WDGVFWSLMYEAGZ-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2,4-dihydroxy-3-oxobutan-2-yl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)C(C)(C(CO)=O)O WDGVFWSLMYEAGZ-UHFFFAOYSA-N 0.000 claims 1
- HLIDCCUMHXLIRM-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(2-hydroxyacetyl)-2-methyl-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)C)=O)C(CO)=O HLIDCCUMHXLIRM-UHFFFAOYSA-N 0.000 claims 1
- LYJIYGZXENLAPE-UHFFFAOYSA-N 8-chloro-1-(2,6-dichlorophenyl)-5-(3,4-dihydroxybutyl)-2-(hydroxymethyl)-1,6-naphthyridin-4-one Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CCC(CO)O LYJIYGZXENLAPE-UHFFFAOYSA-N 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- LYJIYGZXENLAPE-NSHDSACASA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@@H](CO)O LYJIYGZXENLAPE-NSHDSACASA-N 0.000 claims 1
- LYJIYGZXENLAPE-LLVKDONJSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)CC[C@H](CO)O LYJIYGZXENLAPE-LLVKDONJSA-N 0.000 claims 1
- NACUEOVEOGDGII-JTQLQIEISA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@@H](CO)O NACUEOVEOGDGII-JTQLQIEISA-N 0.000 claims 1
- NACUEOVEOGDGII-SNVBAGLBSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)C[C@H](CO)O NACUEOVEOGDGII-SNVBAGLBSA-N 0.000 claims 1
- XDAYAPJRCGNDON-CYBMUJFWSA-N ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@@H](CO)O Chemical compound ClC=1C=NC(=C2C(C=C(N(C=12)C1=C(C=CC=C1Cl)Cl)CO)=O)[C@@H](CO)O XDAYAPJRCGNDON-CYBMUJFWSA-N 0.000 claims 1
- 102000012195 Fructose-1,6-bisphosphatases Human genes 0.000 claims 1
- 108010017464 Fructose-Bisphosphatase Proteins 0.000 claims 1
- 108091007911 GSKs Proteins 0.000 claims 1
- 102000030595 Glucokinase Human genes 0.000 claims 1
- 108010021582 Glucokinase Proteins 0.000 claims 1
- 102000007390 Glycogen Phosphorylase Human genes 0.000 claims 1
- 108010046163 Glycogen Phosphorylase Proteins 0.000 claims 1
- 102000004103 Glycogen Synthase Kinases Human genes 0.000 claims 1
- 102000003886 Glycoproteins Human genes 0.000 claims 1
- 108090000288 Glycoproteins Proteins 0.000 claims 1
- 102100021711 Ileal sodium/bile acid cotransporter Human genes 0.000 claims 1
- 101710156096 Ileal sodium/bile acid cotransporter Proteins 0.000 claims 1
- 229940122199 Insulin secretagogue Drugs 0.000 claims 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 claims 1
- 102000003979 Mineralocorticoid Receptors Human genes 0.000 claims 1
- 108090000375 Mineralocorticoid Receptors Proteins 0.000 claims 1
- 102000023984 PPAR alpha Human genes 0.000 claims 1
- 238000010521 absorption reaction Methods 0.000 claims 1
- 230000001800 adrenalinergic effect Effects 0.000 claims 1
- 239000000674 adrenergic antagonist Substances 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 108010028144 alpha-Glucosidases Proteins 0.000 claims 1
- 239000002333 angiotensin II receptor antagonist Substances 0.000 claims 1
- 229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
- 230000008485 antagonism Effects 0.000 claims 1
- 229940127219 anticoagulant drug Drugs 0.000 claims 1
- 239000002220 antihypertensive agent Substances 0.000 claims 1
- 229940030600 antihypertensive agent Drugs 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 150000002148 esters Chemical class 0.000 claims 1
- 230000023597 hemostasis Effects 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 239000004026 insulin derivative Substances 0.000 claims 1
- 229940012843 omega-3 fatty acid Drugs 0.000 claims 1
- 235000020660 omega-3 fatty acid Nutrition 0.000 claims 1
- 239000006014 omega-3 oil Substances 0.000 claims 1
- 210000002824 peroxisome Anatomy 0.000 claims 1
- 108091008725 peroxisome proliferator-activated receptors alpha Proteins 0.000 claims 1
- 238000000634 powder X-ray diffraction Methods 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662410930P | 2016-10-21 | 2016-10-21 | |
| CN2016102928 | 2016-10-21 | ||
| US201662413292P | 2016-10-26 | 2016-10-26 | |
| PCT/IB2017/056515 WO2018073788A1 (en) | 2016-10-21 | 2017-10-19 | Naphthyridinone derivatives and their use in the treatment of arrhythmia |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| FI3529251T3 true FI3529251T3 (fi) | 2023-01-13 |
Family
ID=60409317
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FIEP17801105.2T FI3529251T3 (fi) | 2016-10-21 | 2017-10-19 | Naftyridinonijohdannaisia ja niiden käyttö rytmihäiriön hoidossa |
Country Status (31)
| Country | Link |
|---|---|
| US (3) | US10266531B2 (enExample) |
| EP (2) | EP4141006A1 (enExample) |
| JP (1) | JP7030802B2 (enExample) |
| KR (1) | KR102540872B1 (enExample) |
| CN (1) | CN109843887B (enExample) |
| AU (2) | AU2017344489C1 (enExample) |
| CL (1) | CL2019001023A1 (enExample) |
| CO (1) | CO2019003894A2 (enExample) |
| CR (1) | CR20190201A (enExample) |
| CU (1) | CU24599B1 (enExample) |
| DO (1) | DOP2019000100A (enExample) |
| EC (1) | ECSP19026973A (enExample) |
| ES (1) | ES2934234T3 (enExample) |
| FI (1) | FI3529251T3 (enExample) |
| HR (1) | HRP20221516T1 (enExample) |
| HU (1) | HUE060882T2 (enExample) |
| IL (1) | IL266128B (enExample) |
| JO (1) | JOP20190086A1 (enExample) |
| LT (1) | LT3529251T (enExample) |
| MX (1) | MX390044B (enExample) |
| PE (1) | PE20190735A1 (enExample) |
| PH (1) | PH12019500849A1 (enExample) |
| PL (1) | PL3529251T3 (enExample) |
| PT (1) | PT3529251T (enExample) |
| RS (1) | RS63841B1 (enExample) |
| SA (1) | SA519401614B1 (enExample) |
| SG (1) | SG11201902529WA (enExample) |
| SI (1) | SI3529251T1 (enExample) |
| TW (1) | TWI759343B (enExample) |
| UY (1) | UY37445A (enExample) |
| WO (1) | WO2018073788A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| CN112585139B (zh) * | 2018-06-27 | 2023-12-01 | 百时美施贵宝公司 | 用作t细胞激活剂的萘啶酮化合物 |
| WO2022074567A1 (en) * | 2020-10-06 | 2022-04-14 | Novartis Ag | Pharmaceutical compositions comprising naphthyridinone derivatives and their use in the treatment of arrhythmia |
| CN115677739B (zh) * | 2021-07-31 | 2025-09-30 | 华南理工大学 | 一种o,o-二氟化硼配合物的制备方法 |
| AR127698A1 (es) * | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
| US20260092074A1 (en) * | 2022-09-23 | 2026-04-02 | Guangzhou Vinnocent Pharmaceutical Limited | Annelated Pyridines as Steroidogenesis Inhibitors, Preparation Method and Use Thereof |
| KR20260015867A (ko) * | 2023-05-24 | 2026-02-03 | 노파르티스 아게 | 질환 또는 장애 치료용 나프티리디논 유도체 |
Family Cites Families (83)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1022214A (en) | 1963-01-31 | 1966-03-09 | Sterling Drug Inc | Novel 1,3-disubstituted-1,4-dihydro-4-oxo-1,7-naphthyridines and their preparation |
| IL51092A0 (en) | 1976-12-10 | 1977-02-28 | Abic Ltd | Naphthyridine derivatives and their preparation |
| JPS57176958A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2-methylthioindole and its preparation |
| JPS57176956A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
| JPS57176957A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | Preparation of 1-(2',6'-dichlorophenyl)-2-indolinone |
| JPS57176959A (en) | 1981-04-24 | 1982-10-30 | Nissan Chem Ind Ltd | 1-(2',6'-dichlorophenyl)-2,3bis(methylthio) indole and its preparation |
| US4617307A (en) | 1984-06-20 | 1986-10-14 | Ciba-Geigy Corporation | Substituted imidazo[1,5-A]pyridine derivatives as aromatase inhibitors |
| US4889861A (en) | 1982-12-21 | 1989-12-26 | Ciba-Geigy Corp. | Substituted imidazo[1,5-a]pyridine derivatives and other substituted bicyclic derivatives and their use as aromatase inhibitors |
| FI77669C (fi) | 1983-04-13 | 1989-04-10 | Ciba Geigy Ag | 20-spiroxaner och analoger, som innehaoller en oeppen ring e, foerfarande foer deras framstaellning samt dessa innehaollande farmaceutiska preparat. |
| US4698341A (en) | 1983-07-30 | 1987-10-06 | Godecke Aktiengesellschaft | Use of 1,6-naphthyridinone derivatives in treating pulmonary thrombosis |
| US4767762A (en) * | 1985-12-23 | 1988-08-30 | Abbott Laboratories | Tricyclic quinoline and naphthyride antibacterials |
| US5120712A (en) | 1986-05-05 | 1992-06-09 | The General Hospital Corporation | Insulinotropic hormone |
| US5118666A (en) | 1986-05-05 | 1992-06-02 | The General Hospital Corporation | Insulinotropic hormone |
| ATE164852T1 (de) | 1990-01-24 | 1998-04-15 | Douglas I Buckley | Glp-1-analoga verwendbar in der diabetesbehandlung |
| IL101860A0 (en) | 1991-05-31 | 1992-12-30 | Ici Plc | Heterocyclic derivatives |
| WO1993011782A1 (en) | 1991-12-19 | 1993-06-24 | Southwest Foundation For Biomedical Research | Cetp inhibitor polypeptide, antibodies against the synthetic polypeptide and prophylactic and therapeutic anti-atherosclerosis treatments |
| IL111785A0 (en) | 1993-12-03 | 1995-01-24 | Ferring Bv | Dp-iv inhibitors and pharmaceutical compositions containing them |
| US5705483A (en) | 1993-12-09 | 1998-01-06 | Eli Lilly And Company | Glucagon-like insulinotropic peptides, compositions and methods |
| US5512549A (en) | 1994-10-18 | 1996-04-30 | Eli Lilly And Company | Glucagon-like insulinotropic peptide analogs, compositions, and methods of use |
| EP0787720B1 (en) | 1994-10-20 | 2003-07-16 | Wakunaga Seiyaku Kabushiki Kaisha | Pyridonecarboxylate derivative or salt thereof and antibacterial containing the same as active ingredient |
| PT897919E (pt) | 1996-04-19 | 2004-11-30 | Wakunaga Pharma Co Ltd | Novos derivados do acido piridonacarboxilico ou seus sais e agentes anti-bacterianos contendo-os como ingrediente activo |
| DE122010000020I1 (de) | 1996-04-25 | 2010-07-08 | Prosidion Ltd | Verfahren zur Senkung des Blutglukosespiegels in Säugern |
| TW492957B (en) | 1996-11-07 | 2002-07-01 | Novartis Ag | N-substituted 2-cyanopyrrolidnes |
| US6136823A (en) | 1996-11-28 | 2000-10-24 | Wakunaga Pharmaceutical Co., Ltd. | Pyridonecarboxylic acid derivatives or salts thereof and drugs containing the same as the active ingredient |
| JP2002517486A (ja) | 1998-06-12 | 2002-06-18 | バーテックス ファーマシューティカルズ インコーポレイテッド | ｐ３８のインヒビター |
| AU5509099A (en) | 1998-08-03 | 2000-02-28 | Basf Corporation | Pyridinones for the treatment of sexual dysfunction |
| GT199900147A (es) | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
| US6197786B1 (en) | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
| CO5150173A1 (es) | 1998-12-10 | 2002-04-29 | Novartis Ag | Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv |
| US6683113B2 (en) | 1999-09-23 | 2004-01-27 | Pharmacia Corporation | (R)-chiral halogenated substituted N,N-Bis-benzyl aminioalcohol compounds useful for inhibiting cholesteryl ester transfer protein activity |
| HUP0301335A3 (en) | 2000-04-12 | 2006-02-28 | Novartis Ag | Combination of organic compounds |
| JP2003040866A (ja) | 2001-07-31 | 2003-02-13 | Nippon Kayaku Co Ltd | Ｎ置換インドール誘導体、その製造法及びそれを有効成分とする害虫防除剤 |
| CN1578781A (zh) * | 2001-09-26 | 2005-02-09 | 拜尔药品公司 | 用作抗糖尿病药物的1,8－萘啶衍生物 |
| AU2003209388A1 (en) | 2002-01-29 | 2003-09-02 | Merck And Co., Inc. | Substituted imidazoles as cannabinoid receptor modulators |
| JP2005529160A (ja) | 2002-05-31 | 2005-09-29 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 糖尿病及び糖尿病−関連障害の処置のための化合物及び組成物 |
| DK1537114T3 (da) | 2002-08-07 | 2006-11-13 | Novartis Ag | Organiske forbindelser som midler til behandling af aldosteronmedierede tilstande |
| CN100447142C (zh) | 2002-11-18 | 2008-12-31 | 诺瓦提斯公司 | 咪唑并[1,5a]吡啶衍生物及治疗醛固酮所介导疾病的方法 |
| WO2005026164A1 (en) | 2003-09-18 | 2005-03-24 | Altana Pharma Ag | Pharmacologically active imidazo[4,5-c]pyridines |
| JP4719681B2 (ja) | 2003-09-23 | 2011-07-06 | メルク・シャープ・エンド・ドーム・コーポレイション | キナゾリンカリウムチャネル阻害剤 |
| JP2007530550A (ja) | 2004-03-26 | 2007-11-01 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物および方法 |
| UA90269C2 (ru) | 2004-04-02 | 2010-04-26 | Мицубиси Танабе Фарма Корпорейшн | Тетрагидрохинолиновые производные и способ их получения |
| DE102004018198A1 (de) | 2004-04-15 | 2005-11-03 | Merck Patent Gmbh | Sulfonamide |
| US7612088B2 (en) | 2004-05-28 | 2009-11-03 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| JP5179174B2 (ja) | 2004-05-28 | 2013-04-10 | ノバルティス ファーマ アーゲー | アルドステロンシンターゼ阻害剤としてのテトラヒドロ−イミダゾ［１，５−ａ］ピリジン誘導体 |
| CA2568164A1 (en) | 2004-05-28 | 2005-12-15 | Speedel Experimenta Ag | Heterocyclic compounds and their use as aldosterone synthase inhibitors |
| LT2502911T (lt) | 2004-06-24 | 2017-09-11 | Vertex Pharmaceuticals Incorporated | Atp surišančios kasetės transporterių moduliatoriai |
| WO2006005726A2 (en) | 2004-07-09 | 2006-01-19 | Speedel Experimenta Ag | Heterocyclic compounds |
| DE102004054215A1 (de) | 2004-11-10 | 2006-05-11 | Merck Patent Gmbh | Pyridopyrimidinonderivate |
| TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716105A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Imidazole compounds |
| TW200716634A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| BRPI0612287A8 (pt) | 2005-06-27 | 2019-01-22 | Exelixis Inc | composição para uso farmacêutico no tratamento de doenças através da medicina nuclear e métodos de uso e para modulação de atividade de receptor nuclear |
| GT200600381A (es) | 2005-08-25 | 2007-03-28 | Compuestos organicos | |
| EP1783114A1 (en) | 2005-11-03 | 2007-05-09 | Novartis AG | N-(hetero)aryl indole derivatives as pesticides |
| JP5460054B2 (ja) | 2005-11-23 | 2014-04-02 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | 腫瘍形成性ｒａｓ特異的細胞障害性化合物およびその使用法 |
| TW200804378A (en) | 2005-12-09 | 2008-01-16 | Speedel Experimenta Ag | Organic compounds |
| US20090156875A1 (en) | 2006-04-04 | 2009-06-18 | Takafumi Tomioka | Methane separation method, methane separation apparatus, and methane utilization system |
| TW200808812A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| TW200808813A (en) | 2006-04-12 | 2008-02-16 | Speedel Experimenta Ag | Imidazo compounds |
| EP1886695A1 (en) | 2006-06-27 | 2008-02-13 | Speedel Experimenta AG | Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist |
| CA2660701A1 (en) | 2006-08-25 | 2008-03-06 | Novartis Ag | Fused imidazole derivatives for the treatment of disorders mediated by aldosterone synthase and/or 11-beta-hydroxylase and/or aromatase |
| EP2094669A2 (en) | 2006-12-18 | 2009-09-02 | Novartis AG | 1-substituted imidazole derivatives and their use as aldosterone synthase inhibitors |
| KR20090090395A (ko) | 2006-12-18 | 2009-08-25 | 노파르티스 아게 | 4-이미다졸릴-1,2,3,4-테트라히드로퀴놀린 유도체 및 알도스테론/11-베타-히드록실라제 억제제로서의 그의 용도 |
| EA200900811A1 (ru) | 2006-12-18 | 2009-12-30 | Новартис Аг | Имидазолы в качестве ингибиторов альдостеронсинтазы |
| RU2009139811A (ru) | 2007-03-29 | 2011-05-10 | Новартис АГ (CH) | Гетероциклические спиросоединения |
| ES2494366T3 (es) * | 2008-02-22 | 2014-09-15 | Otsuka Pharmaceutical Co., Ltd. | Compuesto de benzodiacepina y composición farmacéutica |
| WO2010012745A2 (en) | 2008-07-29 | 2010-02-04 | Boehringer Ingelheim International Gmbh | Benzimidazoles |
| AU2010283632B2 (en) | 2009-08-10 | 2016-08-25 | Ucl Business Plc | Reversible covalent linkage of functional molecules |
| GB0917571D0 (en) | 2009-10-07 | 2009-11-25 | Karobio Ab | Novel estrogen receptor ligands |
| KR20130059400A (ko) | 2010-08-25 | 2013-06-05 | (주)네오팜 | 신규한 헤테로고리 화합물 및 이를 이용한 염증성 질환 치료용 조성물 |
| EP2524915A1 (en) | 2011-05-20 | 2012-11-21 | Sanofi | 2-Amino-3-(imidazol-2-yl)-pyridin-4-one derivatives and their use as VEGF receptor kinase inhibitors |
| ES2561298T3 (es) | 2011-07-12 | 2016-02-25 | F. Hoffmann-La Roche Ag | Compuestos de aminometilquinolona |
| HK1201455A1 (en) | 2012-01-27 | 2015-09-04 | Gilead Sciences Inc | Combination therapies using late sodium ion channel blockers and potassium ion channel blockers |
| EP2855472B1 (en) | 2012-04-05 | 2016-09-14 | Boehringer Ingelheim International GmbH | Naphthyridinone derivatives as inhibitors of cytomegalovirus dna polymerase |
| US9067894B1 (en) | 2013-03-07 | 2015-06-30 | Vanderbilt University | Compound, composition, and method of activating GIRK potassium channel and use of same for treating conditions of interest |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| WO2014152317A2 (en) | 2013-03-15 | 2014-09-25 | Melinta Therapeutics, Inc. | Methods of treating gonorrhea infections using quinolone antibiotics |
| AR096022A1 (es) | 2013-04-11 | 2015-12-02 | Basf Se | Compuestos de pirimidinio sustituido, útiles para combatir plagas de animales |
| WO2015019347A1 (en) | 2013-08-08 | 2015-02-12 | Yeda Research And Development Company Ltd. | Girk as a therapeutic target of immune disorders and a marker of b cell subtypes |
| US20160326165A1 (en) | 2013-12-26 | 2016-11-10 | Kinki University | Alkoxycarbonyl hemiacetal-type ester prodrug of pyridone carboxylic acid antibacterial drug |
| CN106573006A (zh) | 2014-08-21 | 2017-04-19 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为药物的rip1激酶抑制剂杂环酰胺 |
| PE20180252A1 (es) * | 2015-06-09 | 2018-02-02 | Bayer Pharma AG | Moduladores alostericos positivos del receptor muscarinico m2 |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
-
2017
- 2017-06-16 JO JOP/2019/0086A patent/JOP20190086A1/ar unknown
- 2017-10-18 UY UY0001037445A patent/UY37445A/es not_active Application Discontinuation
- 2017-10-19 HR HRP20221516TT patent/HRP20221516T1/hr unknown
- 2017-10-19 AU AU2017344489A patent/AU2017344489C1/en active Active
- 2017-10-19 PE PE2019000829A patent/PE20190735A1/es unknown
- 2017-10-19 LT LTEPPCT/IB2017/056515T patent/LT3529251T/lt unknown
- 2017-10-19 PL PL17801105.2T patent/PL3529251T3/pl unknown
- 2017-10-19 SG SG11201902529WA patent/SG11201902529WA/en unknown
- 2017-10-19 HU HUE17801105A patent/HUE060882T2/hu unknown
- 2017-10-19 EP EP22195204.7A patent/EP4141006A1/en not_active Withdrawn
- 2017-10-19 CU CU2019000042A patent/CU24599B1/es unknown
- 2017-10-19 MX MX2019004484A patent/MX390044B/es unknown
- 2017-10-19 ES ES17801105T patent/ES2934234T3/es active Active
- 2017-10-19 CN CN201780063857.XA patent/CN109843887B/zh active Active
- 2017-10-19 KR KR1020197014044A patent/KR102540872B1/ko active Active
- 2017-10-19 US US15/788,248 patent/US10266531B2/en active Active
- 2017-10-19 TW TW106135836A patent/TWI759343B/zh active
- 2017-10-19 SI SI201731279T patent/SI3529251T1/sl unknown
- 2017-10-19 RS RS20221152A patent/RS63841B1/sr unknown
- 2017-10-19 EP EP17801105.2A patent/EP3529251B1/en active Active
- 2017-10-19 PT PT178011052T patent/PT3529251T/pt unknown
- 2017-10-19 WO PCT/IB2017/056515 patent/WO2018073788A1/en not_active Ceased
- 2017-10-19 FI FIEP17801105.2T patent/FI3529251T3/fi active
- 2017-10-19 CR CR20190201A patent/CR20190201A/es unknown
- 2017-10-19 JP JP2019520981A patent/JP7030802B2/ja active Active
-
2019
- 2019-03-01 US US16/290,313 patent/US10844055B2/en active Active
- 2019-04-15 CL CL2019001023A patent/CL2019001023A1/es unknown
- 2019-04-15 EC ECSENADI201926973A patent/ECSP19026973A/es unknown
- 2019-04-16 CO CONC2019/0003894A patent/CO2019003894A2/es unknown
- 2019-04-16 DO DO2019000100A patent/DOP2019000100A/es unknown
- 2019-04-17 PH PH12019500849A patent/PH12019500849A1/en unknown
- 2019-04-18 SA SA519401614A patent/SA519401614B1/ar unknown
- 2019-04-18 IL IL266128A patent/IL266128B/en active IP Right Grant
-
2020
- 2020-06-29 AU AU2020204341A patent/AU2020204341B2/en active Active
- 2020-10-15 US US17/071,311 patent/US11530213B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI3529251T3 (fi) | Naftyridinonijohdannaisia ja niiden käyttö rytmihäiriön hoidossa | |
| ES2846183T3 (es) | Métodos y composiciones farmacéuticas para el tratamiento de la infección por el virus de la hepatitis B | |
| JP6280546B2 (ja) | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 | |
| CA2717948C (en) | 5imidazoquinolines and pyrimidine derivatives as potent modulators of vegf-driven angiogenic processes | |
| IL299871A (en) | Methods and combinations of KAT6 inhibitors for the treatment of cancer | |
| EP3268490A1 (en) | Substituted 2,3-dihydroimidazo[1,2-c]quinazoline-containing combinations | |
| WO2008128038A2 (en) | Methods and compositions for treating cardiac dysfunctions | |
| RU2019123319A (ru) | Пиразолопиримидины и способы их применения | |
| JP2015516392A5 (enExample) | ||
| UA114177C2 (uk) | ЗАСТОСУВАННЯ ЗАМІЩЕНИХ 2,3-ДИГІДРОІМІДАЗО[1,2-c]ХІНАЗОЛІНІВ | |
| US20140350037A1 (en) | Method of treating proliferative disorders and other pathological conditions mediated by bcr-abl, c-kit, ddr1, ddr2 or pdgf-r kinase activity | |
| US11660301B2 (en) | Combination of ATR kinase inhibitors with PARP inhibitors | |
| HU228516B1 (en) | Use of dopamine d3 receptor ligands for producing pharmaceutical compositions for treating kidney disorders | |
| JP2017014224A (ja) | 帯状疱疹関連痛の急性期疼痛の予防又は治療剤 | |
| SK285587B6 (sk) | Použitie CGRP-antagonistov a inhibítorov uvoľňovania CGRP | |
| KR20080107429A (ko) | 정신병적 장애의 치료 또는 예방용의 신규한 치료학적 배합물 | |
| WO2019180141A1 (en) | Combinations of rogaratinib | |
| CA2587026A1 (en) | Use of dipyridamole in combination with antithrombotics for treatment and prevention of thromboembolic diseases | |
| JP2006501246A5 (enExample) | ||
| Ko | 25 Roles of Central Opioid Receptor Subtypes in Regulating Itch Sensation | |
| Ravichandiran Velayutham et al. | Overview on Biological Activities | |
| JP2012519668A (ja) | ロイシンジッパーおよび滅菌αモチーフを含有するキナーゼ（ＺＡＫ）によって媒介される障害を治療するためのピリミジルアミノベンズアミド誘導体の使用 | |
| KR20080004564A (ko) | 과호산구성 증후군을 위한 피리미딜아미노벤즈아미드유도체 | |
| Burns et al. | H4 Receptor Antagonists and Their Potential Therapeutic Applications | |
| KR20170015218A (ko) | 3-[(3-｛[4-(4-모르폴리닐메틸)-1h-피롤-2-일]메틸렌｝-2-옥소-2,3-디하이드로-1h-인돌-5-일)메틸]-1,3-티아졸리딘-2,4-디온과 egfr tyr 키나제 억제제 사이의 신규한 회합물 |